---
document_datetime: 2024-05-17 10:33:27
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zepatier-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zepatier-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.596967
conversion_datetime: 2025-12-22 20:57:50.336665
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zepatier

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0041               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 03/05/2024                          |                                             | Labelling and PL                 |           |
| IA/0042              | A.7 - Administrative change - Deletion of manufacturing sites                                    | 29/04/2024                          | n/a                                         |                                  |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0040             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                        | 07/09/2023   | n/a        |                 |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| IB/0039             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                               | 14/04/2023   | n/a        |                 |                                   |
| IAIN/0038           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                  | 21/11/2022   | 24/10/2023 | Annex II and PL |                                   |
| IA/0037             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                | 27/09/2022   | n/a        |                 |                                   |
| PSUSA/10519 /202201 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                                                                                                                                                                                                        | 01/09/2022   | n/a        |                 | PRAC Recommendation - maintenance |
| II/0033             | Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS). C.I.13 - Other variations not specifically covered | 07/07/2022   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                     | of studies to the competent authority                                                                                                                                                                                                        |            |            |                       |                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SW/0036             | Post Authorisation Safety Study results - EMEA/H/C/PSR/J/0038 - Variation                                                                                                                                                                    | 24/03/2022 | 02/06/2022 | SmPC, Annex II and PL | The observational study and the systematic review/ meta- analysis did not show an increased risk of hepatocellular carcinoma recurrence in patients treated with direct-acting antivirals. The DAA-PASS study commitment is considered fulfilled and the respective products should be removed from the list of medicines under additional monitoring. |
| II/0034             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                | 05/05/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                        |
| II/0029             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                               | 16/09/2021 | 22/10/2021 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/10519 /202101 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                                                         | 02/09/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                      |
| IB/0032             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 20/08/2021 | 22/10/2021 | Annex II              |                                                                                                                                                                                                                                                                                                                                                        |
| R/0026              | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 25/02/2021 | 06/05/2021 |                       |                                                                                                                                                                                                                                                                                                                                                        |
| IA/0031             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 25/03/2021 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IA/0028             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   | 11/02/2021   | n/a        |                                  |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| IB/0027             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                          | 25/11/2020   | 29/01/2021 | SmPC                             |                                   |
| PSUSA/10519 /202001 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                               | 03/09/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0025             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                     | 28/05/2020   | 29/01/2021 | SmPC, Annex II, Labelling and PL |                                   |
| IB/0023             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                     | 31/01/2020   | 29/01/2021 | SmPC and PL                      |                                   |
| IB/0022             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                               | 09/10/2019   | n/a        |                                  |                                   |
| PSUSA/10519 /201901 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                               | 05/09/2019   | n/a        |                                  | PRAC Recommendation - maintenance |
| IAIN/0021           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority          | 21/06/2019   | 13/01/2020 | Annex II and PL                  |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0019             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                | 19/03/2019   | n/a        |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10519 /201807 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                            | 14/02/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0018/G         | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 17/01/2019   | 13/01/2020 | SmPC and PL            |                                   |
| IB/0016             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                            | 11/09/2018   | n/a        |                        |                                   |
| PSUSA/10519 /201801 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                            | 12/07/2018   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0015              | Transfer of Marketing Authorisation                                                                                                                                                                             | 23/05/2018   | 15/06/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/10519 /201707 | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                            | 08/02/2018   | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0012             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                             | 13/10/2017   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10519 /201701   | Periodic Safety Update EU Single assessment - elbasvir / grazoprevir                                                                                                                                                                                                                                           | 01/09/2017   | n/a        |                       | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-------------------------------------|
| IB/0010               | C.I.1.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a Union referral procedure - The product is not covered by the defined scope of the procedure but the change(s) implements the outcome of the procedure and no new additional data is required to be submitted by the MAH | 05/07/2017   | 30/11/2017 | SmPC, Annex II and PL |                                     |
| IB/0011/G             | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                  | 21/06/2017   | n/a        |                       |                                     |
| II/0007               | B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection                                                                                                                                                                        | 01/06/2017   | n/a        |                       |                                     |
| IA/0009               | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                   | 20/04/2017   | n/a        |                       |                                     |

<div style=\"page-break-after: always\"></div>

| II/0005   | Update of section 4.5 of the SmPC in order to update information regarding drug-drug interaction (DDI) of elbasvir/grazoprevir when co-administrated with sunitinib (tyrosine kinase inhibitor). The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to include some editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 06/04/2017   | 30/11/2017   | SmPC, Labelling and PL   | Co-administration of ZEPATIER with sunitinib may increase sunitinib concentrations leading to an increased risk of sunitinib-associated adverse events. Use with caution; dose adjustment of sunitinib may be required.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0006   | Update of section 5.2 of the SmPC in order to update the information on absolute bioavailability of elbasvir and grazoprevir following recent Company Core Data Sheet (CCDS) safety information update. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                      | 23/03/2017   | 30/11/2017   | SmPC                     | For elbasvir, the absolute bioavailability is estimated to be 32%. For grazoprevir, the absolute bioavailability after a 200 mg single dose ranged from 15 - 27% and after multiple 200 mg doses ranged from 20 - 40%.    |
| IAIN/0004 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                 | 16/12/2016   | 30/11/2017   | SmPC and PL              |                                                                                                                                                                                                                           |
| IB/0003   | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                    | 16/11/2016   | n/a          |                          |                                                                                                                                                                                                                           |
| IA/0001/G | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold                                                                                                                                                                                                                                                                                                                 | 07/10/2016   | n/a          |                          |                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | compared to the originally approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size   |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0002 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                              | 06/10/2016 | n/a |